X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Medivir is focusing on the development of MIV-818 (fostroxacitabine bralpamide), a pro-drug designed to selectively treat hepatocellular carcinoma (HCC).
Lead Product(s): Fostroxacitabine Bralpamide,Pembrolizumab
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hallberg Management AB
Deal Size: $12.3 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 22, 2024
Details:
MIV-818 (fostroxacitabine bralpamide) is DNA inhibitor. It is being evaluated under phase 1/2 clinical development in combination with Lenvima (lenvatinib) for the treatment of hepatocellular carcinoma.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quotient Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Fostrox (fostroxacitabine bralpamide) is an oral nucleotide DNA polymerase inhibitor. It is being developed for the treatment of patients with hepatocellular carcinoma (HCC).
Lead Product(s): Fostroxacitabine Bralpamide
Therapeutic Area: Oncology Product Name: Fostrox
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated in with fostrox in combination with Lenvima for the treatment of primary liver cancer.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated in with fostrox in combination with Lenvima for the treatment of primary liver cancer.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated in with fostrox in combination with Lenvima for the treatment of primary liver cancer.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated for the treatment of primary liver cancer.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated for the treatment of primary liver cancer.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug. Its active metabolite troxacitabine triphosphate (TRX-TP) is then incorporated into rapidly dividing cancer cell's DNA, thereby causing DNA damage and cancer cell death.
Lead Product(s): Fostroxacitabine Bralpamide,Pembrolizumab
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug. Its active metabolite troxacitabine triphosphate (TRX-TP) is then incorporated into rapidly dividing cancer cell's DNA, thereby causing DNA damage and cancer cell death.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug. Its active metabolite troxacitabine triphosphate (TRX-TP) is then incorporated into rapidly dividing cancer cell's DNA, thereby causing DNA damage and cancer cell death.
Lead Product(s): Fostroxacitabine Bralpamide,Pembrolizumab
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2023
Details:
Fostroxacitabine bralpamide (Fostrox, MIV-818) is a pro-drug designed to selectively treat liver cancers and to minimize side effects. It has the potential to become the first liver-targeted and orally administered drug for patients with HCC and other forms of liver cancer.
Lead Product(s): Fostroxacitabine Bralpamide,Pembrolizumab
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
Fostrox (fostroxacitabine bralpamide) induces DNA damage and tumour cell death, potentially leading to increased tumour antigen presentation and an increased immune response, generating potential for combining with a checkpoint inhibitor like anti-PD-1.
Lead Product(s): Fostroxacitabine Bralpamide,Pembrolizumab
Therapeutic Area: Oncology Product Name: Fostrox
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
Fostrox (fostroxacitabine bralpamide) has the potential to be the first liver cancer-targeted and orally administered drug that can help patients with HCC and other forms of liver cancer.
Lead Product(s): Fostroxacitabine Bralpamide,Pembrolizumab
Therapeutic Area: Oncology Product Name: Fostrox
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
MIV-818 (fostroxacitabine bralpamide) an orally administered troxacitabine-based nucleotide prodrug, rapidly metabolized by human hepatocytes, directing high levels of the chain-terminating nucleotide tri-phosphate to the liver, while minimizing exposure to other organs.
Lead Product(s): Fostroxacitabine Bralpamide,Pembrolizumab
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
